You have found 23 entries. Starting with analyses of the most recently published documents, the list shows in orange the type of entry, year the original document was published (or if one of our own documents, the year last updated), and the type of file you will download when you click on the title. In blue is the document’s title followed by a brief description.
Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Re-order the list by the most recently added or updated entries or by the main topic addressed
If you have not found what you want you could:
Tab back to the Subject search page/tab to amend your original search.
Try a new search (clears your previous selection).
Instead try a free text search for documents which contain the words you specify.
Or try browsing back issues of the magazine or the more recent email bulletins.
Try the information services provided by partner agencies.
Tried everything? E-mail the Findings editor for help by clicking on this logo
MATRIX CELL 2018 HTM file
Drug Treatment Matrix cell A3: Interventions; Medical treatment
Key studies on the effectiveness of medical interventions and treatment in medical settings.
STUDY 2018 HTM file
The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom
Buprenorphine may be associated with a lower risk of mortality than methadone among people engaged in opioid substitution treatment – but is the pattern of short treatment duration in the UK preventing maximal impact at a population level?
DOCUMENT 2018 HTM file
Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63
Expanding access to medication is an important public health strategy for tackling opioid use disorder, concludes US government agency guidelines. While some people stop using opioids without medication, many benefit from access to methadone, naltrexone, and buprenorphine for varying lengths of time, including lifelong treatment.
MATRIX CELL 2018 HTM file
Drug Treatment Matrix cell B3: Practitioners; Medical treatment
Seminal and key research and reviews on the influence of the practitioner in the medical treatment of drug dependence. Investigates the how clinician-patient relationships might be affected by enforcing clinic rules and the potential importance of doctors forming a “whole person’ relationship with patients.
MATRIX CELL 2018 HTM file
Drug Treatment Matrix cell D3: Organisational functioning; Medical treatment
Seminal and key studies on how treatment organisations affect the implementation and effectiveness of medical interventions and treatment in medical settings. Focus is on UK and US understandings of what counts as a ‘recovery-oriented’ service and on US, Australian and Canadian studies which discovered and validated elements of these visions even before they were articulated.
DOCUMENT 2017 HTM file
Drug misuse and dependence: UK guidelines on clinical management
Last published in 2007, there is no more important document for UK clinicians involved in treating problem drug use than the so-called ‘Orange guidelines’. This major update offers detailed guidance on the range of problems, settings and patients clinicians encounter, substantially informing judgements of what constitutes good medical practice.
STUDY 2015 HTM file
Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study
Primary care methadone patients in Ireland were nearly four times more likely to die during periods out of treatment; the first few weeks after leaving were the peak risk period. The study’s support for unbroken, long-term treatment runs counter to recent UK government policy.
STUDY 2015 HTM file
Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial
Unique trial tests what emergency doctors should do when screening identifies opioid dependence. More effective at promoting treatment and curbing opioid use than referral and brief advice was, it seems, actually initiating treatment in the form of buprenorphine maintenance.
STUDY 2014 HTM file
Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville)
From France the first study to randomly allocate patients to start methadone maintenance either in primary care or at a specialist centre found primary care more attractive to patients, and no less effective at reducing street-opioid use and promoting engagement and retention.
STUDY 2014 HTM file
Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial
Among patients dependent on prescription opioids, ongoing maintenance therapy using a legal opiate substitute (buprenorphine–naloxone) produced better outcomes than tapered withdrawal, with patients less likely to have used illicit opioids and considerably more likely to have remained in their allocated treatment.
Select search results page
NEXT 1 2 3